Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabetic Retinopathy: A Variant Of A Growth Factor Responsible For Abnormal Blood Vessel Growth And Eye Damages

19.09.2007
Targeting the inflammation caused by VEGF could give better quality of life to patients affected by this progressive disease, say UK scientists

A variant form of a common growth factor, called VEGF (vascular endothelial growth factor) was identified that is responsible for the inflammation and altered retinal vascularisation that occurs in diseases such as diabetic retinopathy (DR). It could become the target for novel therapies that will help to solve, or at least to ease, a pathology which is poorly treatable by common drugs. The announcement was made yesterday by Professor David T. Shima, Group Leader at the University College of London, Institute of Ophthalmology, at the European Meeting on Vascular Biology and Medicine, held in parallel with the Fourth Annual Meeting of EVGN (www.evgn.org), network of excellence on cardiovascular disease.

Diabetic retinopathy is a leading cause of blindness and is characterized by the invasive growth and abnormal function of blood vessels within the retina, that obstructs vision and triggers other unwanted effects. With an estimate of 500.000 new cases of severe disease per year in Western Countries it is rightly considered a sanitary priority. Many research groups are focussing on potential targets, but so far no effective pharmacological approaches have been proven to substitute the current (destructive) surgical therapies.

David T. Shima and colleagues focused on a growth factor known to be produced during ischemic conditions, when the eye suffers from lack of oxygen. VEGF, this is its name, counterbalances this condition by promoting blood vessel growth. In diabetic retinopathy VEGF is part of an adaptive response to ischemia, that unfortunately in the long run becomes noxious per se.

... more about:
»VEGF »retinopathy »vascular cells »vessel

“We observed – explained the scientist – that, blood vessels in the ischemic retina do regrow but in a disorganized way: they form clumps instead of a fine mesh-like network. UK scientists asked why and clarified the role of VEGF.

“We decided to further characterize the VEGF activity responsible for the abnormal response and identified one alternative form (or isoform) called VEGF 164, that drives not only ocular neovascularization and vascular permeability, but also an undesirable inflammatory reaction. When this form is genetically or pharmaceutically inhibited the pathological neovascularization is inhibited as well, and blood vessels sprout normally”. Further analysis spotted a specific region within this molecule that is the major cause of inflammation, another characteristic of DR. Again, mutations in this region abolish the undesired pro-inflammatory effects

“Certainly, the inflammatory function of VEGF 164 represents a promising target for the treatment of diabetic retinopathy. However there is one problem to solve: VEGF has a second, beneficial role as it protects neurons from ischemic death. Its complete elimination would trigger unwanted consequences and further research is needed to understand this apparent contradiction. Better understanding of the risks and benefits could pave the way for the treatment of this sight-threatening human disease”.

Run jointly with the European Vascular Biology Organization (EVBO) and the British Atherosclerosis Society and articulated over a three day period (September 17-20), the EVGN Meeting will take place in parallel with the 4th European Meeting on Vascular Biology and Medicine (EMVBM), gathering more than 400 scientists from all over Europe with representatives from the rest of the world.

The European Vascular Genomics Network (EVGN) is the first Network of excellence on cardiovascular disease funded by the European Commission under the 6th Framework Programme "Life sciences, genomics and biotechnology for health" (Contract Number: LSHMCT- 2003-503254).

The Conference is supported by an unrestricted educational grant from Laboratoires SERVIER.

Francesca Noceti | alfa
Further information:
http://www.evgn.org/
http://www.ifom-ieo-campus.it

Further reports about: VEGF retinopathy vascular cells vessel

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>